[开放获取]    特殊部位银屑病系统治疗临床研究进展

doi:10.35541/cjd.20230190

中华皮肤科杂志 ›› 2024, e20230190.doi: 10.35541/cjd.20230190

[开放获取] 特殊部位银屑病系统治疗临床研究进展

郝丹,王怡怡,肖月,闫薇,李薇

四川大学华西医院皮肤科，成都 610041

收稿日期:2023-04-06 修回日期:2023-07-27 发布日期:2024-02-22
通讯作者: 李薇 E-mail:liwei476@wchscu.cn

Systemic treatment options for psoriasis in special areas

Hao Dan, Wang Yiyi, Xiao Yue, Yan Wei, Li Wei

Department of Dermatology, West China Hospital, Sichuan University, Chengdu 610041, China

Received:2023-04-06 Revised:2023-07-27 Published:2024-02-22
Contact: Li Wei E-mail:liwei476@wchscu.cn

摘要/Abstract

摘要： 【摘要】特殊部位银屑病包括发病于头皮、甲、手掌/足跖和生殖器等部位的银屑病，通常存在诊断和治疗不足、对常规治疗应答不佳等情况。本文对传统系统性药物、生物制剂和小分子靶向口服药物用于特殊部位银屑病治疗的有效性和安全性临床证据进行总结和更新，为临床医生针对患者情况个体化选择治疗药物提供参考。

关键词: 银屑病, 特殊部位银屑病, 肿瘤坏死因子α抑制剂, 白细胞介素17抑制剂, 白细胞介素23抑制剂, 磷酸二酯酶4抑制剂, 酪氨酸激酶2抑制剂

Abstract: 【Abstract】 Psoriasis in special areas affects the scalp, nails, palms/soles, and genital sites, and inadequate diagnosis and treatment, as well as poor response to conventional therapies, remain problems in clinical practice. The review summarizes and updates clinical evidence on the efficacy and safety of conventional systemic agents, biologics, and oral small-molecule targeted agents for the treatment of psoriasis in special areas, providing a reference for clinicians to individualize therapies for their patients.

Key words: Psoriasis, Psoriasis in special areas, Tumor necrosis factor α inhibitors, Interleukin-17 inhibitors, Interleukin-23 inhibitors, Phosphodiesterase 4 inhibitors, Tyrosine kinase 2 inhibitors

郝丹王怡怡肖月闫薇李薇. [开放获取] 特殊部位银屑病系统治疗临床研究进展[J]. 中华皮肤科杂志, 2024,e20230190. doi:10.35541/cjd.20230190

Hao Dan, Wang Yiyi, Xiao Yue, Yan Wei, Li Wei. Systemic treatment options for psoriasis in special areas[J]. Chinese Journal of Dermatology,2024,e20230190. doi:10.35541/cjd.20230190

参考文献 55

［1］	中华医学会皮肤性病学分会银屑病专业委员会. 银屑病生物制剂达标治疗专家共识［J］. 中华皮肤科杂志, 2023,56（3）:191⁃203. doi: 10.35541/cjd.20220652.
［2］	Galluzzo M, Talamonti M, Cioni A, et al. Efficacy of tildrakizumab for the treatment of difficult⁃to⁃treat areas: scalp, nail, palmoplantar and genital psoriasis［J］. J Clin Med, 2022,11（9）:2631. doi: 10.3390/jcm11092631.
［3］	Lanna C, Galluzzi C, Zangrilli A, et al. Psoriasis in difficult to treat areas: treatment role in improving health⁃related quality of life and perception of the disease stigma［J］. J Dermatolog Treat, 2022,33（1）:531⁃534. doi: 10.1080/09546634.2020.1770175.
［4］	Egeberg A, See K, Garrelts A, et al. Epidemiology of psoriasis in hard⁃to⁃treat body locations: data from the Danish skin cohort［J］. BMC Dermatol, 2020,20（1）:3. doi: 10.1186/s12895⁃020⁃00099⁃7.
［5］	Strober B, Ryan C, van de Kerkhof P, et al. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council［J］. J Am Acad Dermatol, 2020,82（1）:117⁃122. doi: 10.1016/j.jaad.2019.08.026.
［6］	Ghafoor R, Patil A, Yamauchi P, et al. Treatment of scalp psoriasis［J］. J Drugs Dermatol, 2022,21（8）:833⁃837. doi: 10. 36849/JDD.6498.
［7］	Camela E, Ocampo⁃Garza S S, Cinelli E, et al. Therapeutic update of biologics and small molecules for scalp psoriasis: a systematic review［J］. Dermatol Ther, 2021,34（2）:e14857. doi: 10.1111/dth.14857.
［8］	Mosca M, Hong J, Hadeler E, et al. Scalp psoriasis: a literature review of effective therapies and updated recommendations for practical management［J］. Dermatol Ther（Heidelb）, 2021,11（3）:769⁃797. doi: 10.1007/s13555⁃021⁃00521⁃z.
［9］	Thaçi D, Unnebrink K, Sundaram M, et al. Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the BELIEVE study［J］. J Eur Acad Dermatol Venereol, 2015,29（2）:353⁃360. doi: 10.1111/jdv.12553.
［10］	Reich K, Leonardi C, Lebwohl M, et al. Sustained response with ixekizumab treatment of moderate⁃to⁃severe psoriasis with scalp involvement: results from three phase 3 trials（UNCOVER⁃1, UNCOVER⁃2, UNCOVER⁃3）［J］. J Dermatolog Treat, 2017,28（4）:282⁃287. doi: 10.1080/09546634.2016.1249820.
［11］	Kamata M, Tada Y. Safety of biologics in psoriasis［J］. J Dermatol, 2018,45（3）:279⁃286. doi: 10.1111/1346⁃8138.14096.
［12］	Ten Bergen LL, Petrovic A, Krogh Aarebrot A, et al. The TNF/IL⁃23/IL⁃17 axis⁃head⁃to⁃head trials comparing different biologics in psoriasis treatment［J］. Scand J Immunol, 2020,92（4）:e12946. doi: 10.1111/sji.12946.
［13］	Bagel J, Duffin KC, Moore A, et al. The effect of secukinumab on moderate⁃to⁃severe scalp psoriasis: results of a 24⁃week, randomized, double⁃blind, placebo⁃controlled phase 3b study ［J］. J Am Acad Dermatol, 2017,77（4）:667⁃674. doi: 10.1016/j.jaad.2017.05.033.
［14］	Elewski B, Rich P, Lain E, et al. Efficacy of brodalumab in the treatment of scalp and nail psoriasis: results from three phase 3 trials［J］. J Dermatolog Treat, 2022,33（1）:261⁃265. doi: 10.1080/ 09546634.2020.1749546.
［15］	Merola JF, Warren RB, Han G. Bimekizumab response maintenance in high⁃impact areas in patients with moderate to severe plaque psoriasis: pooled results through 96 weeks of the BE SURE, BE READY, and BE RADIANT phase 3/3b trials ［J］. J Eur Acad Dermatol, 2022,87（3, Supplement）:AB24. doi: 10.1016/j.jaad.2022.06.131.
［16］	George M. Selected poster abstracts from MauiDerm 2021 for dermatologists［J］. J Clin Aesthet Dermatol, 2021,14（5 Suppl 1）:S8⁃S30.
［17］	Foley P, Gordon K, Griffiths CEM, et al. Efficacy of guselkumab compared with adalimumab and placebo for psoriasis in specific body regions: a secondary analysis of 2 randomized clinical trials［J］. JAMA Dermatol, 2018,154（6）:676⁃683. doi: 10.1001/jamadermatol.2018.0793.
［18］	Menter M A, Murakawa G J, Glover H, et al. Clearance of head and neck involvement in plaque psoriasis with tildrakizumab treatment in the phase 3 RESURFACE 1 study［J］. J Eur Acad Dermatol Venereol, 2020,34（12）:e803⁃e805. doi: 10.1111/jdv. 16648.
［19］	Reich K, Rich P, Maari C, et al. Efficacy and safety of mirikizumab（LY3074828） in the treatment of moderate⁃to⁃severe plaque psoriasis: results from a randomized phase II study［J］. Br J Dermatol, 2019,181（1）:88⁃95. doi: 10.1111/bjd.17628.
［20］	Gerdes S, Bräu B, Hoffmann M, et al. Real⁃world effectiveness of guselkumab in patients with psoriasis: health⁃related quality of life and efficacy data from the noninterventional, prospective, German multicenter PERSIST trial［J］. J Dermatol, 2021,48（12）:1854⁃1862. doi: 10.1111/1346⁃8138.16128.
［21］	Papadimitriou I, Bakirtzi K, Katoulis A, et al. Scalp psoriasis and biologic agents: a review［J］. Skin Appendage Disord, 2021,7（6）:439⁃448. doi: 10.1159/000517806.
［22］	Bai F, Li GG, Liu Q, et al. Short⁃term efficacy and safety of IL⁃17, IL⁃12/23, and IL⁃23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: a systematic review and network meta⁃analysis of randomized controlled trials［J］. J Immunol Res, 2019,2019:2546161. doi: 10.1155/2019/2546161.
［23］	Rich P, Gooderham M, Bachelez H, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult⁃to⁃treat nail and scalp psoriasis: results of 2 phase Ⅲ randomized, controlled trials（ESTEEM 1 and ESTEEM 2）［J］. J Am Acad Dermatol, 2016,74（1）:134⁃142. doi: 10.1016/j.jaad.2015.09.001.
［24］	Van Voorhees AS, Stein Gold L, Lebwohl M, et al. Efficacy and safety of apremilast in patients with moderate⁃to⁃severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study［J］. Br J Dermatol, 2021,185（4）:840⁃842. doi: 10.1111/bjd.20083.
［25］	Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52⁃week, randomized, double⁃blinded, placebo⁃controlled phase 3 POETYK PSO⁃1 trial［J］. J Am Acad Dermatol, 2023,88（1）:29⁃39. doi: 10.1016/j.jaad.2022.07.002.
［26］	Strober B, Thaci D, Sofen H, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52⁃week, randomized, double⁃blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial［J］. J Am Acad Dermatol, 2023,88（1）:40⁃51. doi: 10.1016/j.jaad.2022.08.061.
［27］	Blauvelt A, Rich P, Sofen H, et al. Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, versus placebo in scalp, nail, and palmoplantar psoriasis: subset analyses of the phase 3 POETYK PSO⁃1 and PSO⁃2 trials［A］; proceedings of the FC PANP 22 Dermatology Conference［C］, Scottsdale, AZ, US, June 3⁃5, 2022.
［28］	Kaeley GS, Eder L, Aydin SZ, et al. Nail psoriasis: diagnosis, assessment, treatment options, and unmet clinical needs［J］. J Rheumatol, 2021,48（8）:1208⁃1220. doi: 10.3899/jrheum.201471.
［29］	Krajewska⁃Wlodarczyk M, Zuber Z, Owczarczyk⁃Saczonek A. Ultrasound evaluation of the effectiveness of the use of acitretin in the treatment of nail psoriasis［J］. J Clin Med, 2021,10（10）:2122. doi: 10.3390/jcm10102122.
［30］	Augustin M, Landeck L, Diemert S, et al. Long⁃term treatment with dimethyl fumarate for plaque psoriasis in routine practice: good overall effectiveness and positive effect on impactful areas［J］. Dermatol Ther（Heidelb）, 2022,12（5）:1121⁃1131. doi: 10. 1007/s13555⁃022⁃00714⁃0.
［31］	Mrowietz U, Kircik L, Reich K, et al. Tepilamide fumarate（PPC⁃06） extended release tablets in patients with moderate⁃to⁃severe plaque psoriasis: safety and efficacy results from the randomized, double⁃blind, placebo⁃controlled AFFIRM study［J］. J Clin Aesthet Dermatol, 2022,15（1）:53⁃58.
［32］	Hadeler E, Mosca M, Hong J, et al. Nail psoriasis: a review of effective therapies and recommendations for management［J］. Dermatol Ther（Heidelb）, 2021,11（3）:799⁃831. doi: 10.1007/s13555⁃021⁃00523⁃x.
［33］	Luger TA, Barker J, Lambert J, et al. Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate⁃to⁃severe psoriasis［J］. J Eur Acad Dermatol Venereol, 2009,23（8）:896⁃904. doi: 10.1111/j.1468⁃3083.2009. 03211.x.
［34］	Reich K, Ortonne JP, Kerkmann U, et al. Skin and nail responses after 1 year of infliximab therapy in patients with moderate⁃to⁃severe psoriasis: a retrospective analysis of the EXPRESS Trial［J］. Dermatology, 2010,221（2）:172⁃178. doi: 10.1159/000317 775.
［35］	Elewski BE, Baker CS, Crowley JJ, et al. Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase⁃3, randomized, placebo⁃controlled trial［J］. J Eur Acad Dermatol Venereol, 2019,33（11）:2168⁃2178. doi: 10.1111/jdv.15793.
［36］	Al⁃Mutairi N, Nour T, Al⁃Rqobah D. Onychomycosis in patients of nail psoriasis on biologic therapy: a randomized, prospective open label study comparing etanercept, infliximab and adalimumab［J］. Expert Opin Biol Ther, 2013,13（5）:625⁃629. doi:10.1517/14712598.2013.783561.
［37］	Reich K, Sullivan J, Arenberger P, et al. Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5⁃year results from the randomized placebo⁃controlled TRANSFIGURE study ［J］. Br J Dermatol, 2021,184（3）:425⁃436. doi: 10.1111/bjd. 19262.
［38］	Wasel N, Thaci D, French LE, et al. Ixekizumab and ustekinumab efficacy in nail psoriasis in patients with moderate⁃to⁃severe psoriasis: 52⁃week results from a phase 3, head⁃to⁃head study（IXORA⁃S）［J］. Dermatol Ther（Heidelb）, 2020,10（4）:663⁃670. doi: 10.1007/s13555⁃020⁃00383⁃x.
［39］	Blauvelt A, Leonardi C, Elewski B, et al. A head⁃to⁃head comparison of ixekizumab vs. guselkumab in patients with moderate⁃to⁃severe plaque psoriasis: 24⁃week efficacy and safety results from a randomized, double⁃blinded trial［J］. Br J Dermatol, 2021,184（6）:1047⁃1058. doi: 10.1111/bjd.19509.
［40］	Reich K, Gooderham M, Bewley A, et al. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study［J］. J Eur Acad Dermatol Venereol, 2018,32（3）:397⁃402. doi: 10. 1111/jdv.14738.
［41］	Merola JF, Elewski B, Tatulych S, et al. Efficacy of tofacitinib for the treatment of nail psoriasis: two 52⁃week, randomized, controlled phase 3 studies in patients with moderate⁃to⁃severe plaque psoriasis［J］. J Am Acad Dermatol, 2017,77（1）:79⁃87. e71. doi: 10.1016/j.jaad.2017.01.053.
［42］	Merola JF, Qureshi A, Husni ME. Underdiagnosed and undertreated psoriasis: nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails［J］. Dermatol Ther, 2018,31（3）:e12589. doi: 10.1111/dth.12589.
［43］	Shah S, Nikam B, Kale M, et al. Safety and efficacy profile of oral cyclosporine vs oral methotrexate vs oral acitretin in palmoplantar psoriasis: a hospital based prospective investigator blind randomized controlled comparative study［J］. Dermatol Ther, 2021,34（1）:e14650. doi: 10.1111/dth.14650.
［44］	Leonardi C, Langley RG, Papp K, et al. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo⁃controlled, double⁃blind trial［J］. Arch Dermatol, 2011,147（4）:429⁃436. doi: 10.1001/archdermatol. 2010.384.
［45］	Menter A, Warren RB, Langley RG, et al. Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate⁃to⁃severe plaque psoriasis and non⁃pustular palmoplantar involvement: results from three phase 3 trials（UNCOVER⁃1, UNCOVER⁃2 and UNCOVER⁃3）［J］. J Eur Acad Dermatol Venereol, 2017,31（10）:1686⁃1692. doi: 10.1111/jdv.14237.
［46］	Gottlieb AB, Kubanov A, Van Doorn M, et al. Sustained efficacy of secukinumab in patients with moderate⁃to⁃severe palmoplantar psoriasis: 2.5⁃year results from GESTURE, a randomized, double⁃blind, placebo⁃controlled trial［J］. Br J Dermatol, 2020,182（4）:889⁃899. doi: 10.1111/bjd.18331.
［47］	Gottlieb A, Sullivan J, van Doorn M, et al. Secukinumab shows significant efficacy in palmoplantar psoriasis: results from GESTURE, a randomized controlled trial［J］. J Am Acad Dermatol, 2017,76（1）:70⁃80. doi: 10.1016/j.jaad.2016.07.058.
［48］	Reolid A, Armesto S, Sahuquillo⁃Torralba A, et al. Secukinumab is effective in the treatment of recalcitrant palmoplantar psoriasis and palmoplantar pustular psoriasis in a daily practice setting［J］. J Am Acad Dermatol, 2022,87（3）:705⁃709. doi: 10. 1016/j.jaad.2022.05.047.
［49］	Megna M, Tommasino N, Potestio L, et al. Real⁃world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28⁃week retrospective study［J］. J Dermatolog Treat, 2022,33（6）:2813⁃2820. doi: 10. 1080/09546634.2022.2081655.
［50］	Bissonnette R, Pariser DM, Wasel NR, et al. Apremilast, an oral phosphodiesterase⁃4 inhibitor, in the treatment of palmoplantar psoriasis: results of a pooled analysis from phase II PSOR⁃005 and phase Ⅲ efficacy and safety trial evaluating the effects of apremilast in psoriasis（ESTEEM） clinical trials in patients with moderate to severe psoriasis［J］. J Am Acad Dermatol, 2016,75（1）:99⁃105. doi: 10.1016/j.jaad.2016.02.1164.
［51］	Spencer RK, Elhage KG, Jin JQ, et al. Apremilast in palmoplantar psoriasis and palmoplantar pustulosis: a systematic review and meta⁃analysis［J］. Dermatol Ther（Heidelb）, 2023,13（2）:437⁃451. doi: 10.1007/s13555⁃022⁃00877⁃w.
［52］	Ioannides D, Antonakopoulos N, Chasapi V, et al. A real⁃world, non⁃interventional, prospective study of the effectiveness and safety of apremilast in bio⁃naive adults with moderate plaque psoriasis treated in the routine care in Greece ⁃ the ′APRAISAL′ study［J］. J Eur Acad Dermatol Venereol, 2022,36（11）:2055⁃2063. doi:10.1111/jdv.18166.
［53］	Hong JJ, Mosca ML, Hadeler EK, et al. Genital and inverse/intertriginous psoriasis: an updated review of therapies and recommendations for practical management［J］. Dermatol Ther（Heidelb）, 2021,11（3）:833⁃844. doi: 10.1007/s13555⁃021⁃00536⁃ 6.
［54］	Ryan C, Menter A, Guenther L, et al. Efficacy and safety of ixekizumab in a randomized, double⁃blinded, placebo⁃controlled phase Ⅲb study of patients with moderate⁃to⁃severe genital psoriasis［J］. Br J Dermatol, 2018,179（4）:844⁃852. doi: 10. 1111/bjd.16736.
［55］	Guenther L, Potts Bleakman A, Weisman J, et al. Ixekizumab results in persistent clinical improvement in moderate⁃to⁃severe genital psoriasis during a 52 week, randomized, placebo⁃controlled, phase 3 clinical trial［J］. Acta Derm Venereol, 2020, 100（1）: adv00006. doi:10.2340/00015555⁃3353.

[1]	陈星宇姚煦. 中性粒细胞在炎症性皮肤病中的研究进展[J]. 中华皮肤科杂志, 2024, 0(3): 20220865-e20220865.
[2]	吴玉冰王晓宇安彬祎吴莹莹桑红孔庆涛. 环鸟苷酸-腺苷酸合成酶-干扰素基因刺激因子信号通路在银屑病发病中的作用[J]. 中华皮肤科杂志, 2024, 0(3): 20230394-e20230394.
[3]	朱婷婷张学军. 阿普米司特在斑块状银屑病治疗中的研究进展[J]. 中华皮肤科杂志, 2024, 0(3): 20230448-e20230448.
[4]	宗杨永怡马楚君苏忠兰. 银屑病生物制剂治疗后湿疹化发生机制及应对策略[J]. 中华皮肤科杂志, 2024, 0(3): 20220578-e20220578.
[5]	王煜坤刘洁. 深度学习在非肿瘤性皮肤病中的应用进展[J]. 中华皮肤科杂志, 2024, 0(3): 20220660-e20220660.
[6]	王诗琪王爱平李航李若瑜. 趾甲银屑病与指甲银屑病的皮肤镜特征比较[J]. 中华皮肤科杂志, 2024, 57(2): 161-165.
[7]	付丹丹李佳林付修宇张芯育胡华宋向凤田中伟. S100A10蛋白在银屑病皮损的表达及对小鼠银屑病样皮炎模型的影响[J]. 中华皮肤科杂志, 2023, 56(9): 839-844.
[8]	刘小扬赵琰蔡林张建中. 银屑病患者白细胞介素17拮抗剂治疗后出现特应性皮炎样皮疹4例分析与文献回顾[J]. 中华皮肤科杂志, 2023, 56(9): 845-848.
[9]	陈小敏张景展丁媛康晓静. 二甲双胍治疗银屑病的研究进展[J]. 中华皮肤科杂志, 2023, 56(8): 799-802.
[10]	闪莹常晓彤左亚刚. 自身免疫性疱病的表位扩展现象[J]. 中华皮肤科杂志, 2023, 56(7): 702-705.
[11]	唐志铭荆梦晴陆鹭单霄张翠侠张晓宇孟飒. 犀地凉血方通过LncRNA NEAT1/miR-485-5p/ STAT3调控网络对HaCaT细胞增殖、凋亡影响的研究[J]. 中华皮肤科杂志, 2023, 56(7): 642-650.
[12]	中华医学会皮肤性病学分会银屑病专业委员会. 中国银屑病诊疗指南（2023版）[J]. 中华皮肤科杂志, 2023, 56(7): 573-625.
[13]	蒋晓妍高敏张晓艳刘宁远. 白细胞介素17和白细胞介素23拮抗剂治疗脓疱型银屑病研究进展[J]. 中华皮肤科杂志, 2023, 56(7): 689-692.
[14]	中国医师协会皮肤科医师分会中华医学会皮肤性病学分会空军军医大学西京医院中国银屑病患者饮食指南制订工作组. 中国银屑病患者饮食管理指南（2023）[J]. 中华皮肤科杂志, 2023, 56(5): 389-401.
[15]	连盼盼刘军苏忠兰王宏伟. 过氧化物酶体增殖物激活受体γ对皮肤生理功能和病理过程的影响[J]. 中华皮肤科杂志, 2023, 56(4): 365-368.

[开放获取] 特殊部位银屑病系统治疗临床研究进展

Systemic treatment options for psoriasis in special areas

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 55

相关文章 15

Metrics

本文评价

推荐阅读 10